Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Entrada Therapeutics (TRDA): Can Shares Climb +270% to Hit the $19 Analyst Target?

Entrada Therapeutics (TRDA): Can Shares Climb +270% to Hit the $19 Analyst Target?

Key Takeaways

  • The $19 central target is the rounded arithmetic mean of four verifiable, current analyst price targets, which average about $18.75 and range from $10 to $25.
  • With TRDA trading near $5, reaching $19 would require a roughly 270% rise — a very large move for a clinical-stage biotech.
  • The analyst range is unusually wide ($10 to $25), signaling deep disagreement about the durability of early clinical data and the path to value.
  • The strongest supports are the ENTR-601-44 program's clinically meaningful functional gains, upcoming higher-dose data, and a cash position expected to fund operations into 2027.
  • The biggest risks are disappointing ENTR-601-45 biomarker results, a recent downgrade to Neutral from H.C. Wainwright, and ongoing cash burn with minimal revenue.
  • Because targets hinge on binary clinical readouts rather than near-term earnings, the $19 figure represents a multi-year scenario, not a short-term forecast.
  • For more detail on this company's major developments and daily action, explore the Major News and Today's Price Move pages, review the Forecast, and check the Earnings page.
  • Readers looking for automated market insight can explore Trending AI Robots for data-driven trading ideas.

Breaking Down the Analyst Targets

Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company developing its Endosomal Escape Vehicle (EEV) platform for Duchenne muscular dystrophy and other neuromuscular conditions. The most recent individually attributable analyst targets are $10 (Roth MKM, Buy, November 2026), $25 (Evercore ISI, Buy, October 2026), $17 (Guggenheim, Buy, June 2026), and $23 (Oppenheimer, Outperform, September 2026). These four average $18.75, which rounds to the $19 central target used here, with a low-to-high range of $10 to $25.

The spread is telling. Roth MKM cut its target twice — most recently from $11 to $10 after October ENTR-601-45 biomarker results fell short of expectations — while Evercore ISI has held its $25 target on conviction that ENTR-601-44's higher-dose data will validate the platform. That divergence is why this stock carries a "Strong Buy" rating on some trackers and a "Hold" on others. H.C. Wainwright downgraded the shares to Neutral in May 2026, a materially cautious signal amid otherwise bullish coverage. No single target should be treated as a guarantee, and the mean is not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The stock has traded in a 52-week range of roughly $4.11 to $16.45 and recently sat near $5, well below its earlier highs. Reaching $19 would require an increase of about 270%, which is a very large move. For a company generating less than $1 million in quarterly revenue and reporting a net loss, any such advance would depend almost entirely on clinical catalysts rather than earnings. The most plausible path would run through positive ENTR-601-44 longer-duration and higher-dose datasets expected around the fourth quarter of 2026 and first quarter of 2027, followed by renewed investor confidence in the broader Duchenne franchise and its partnered VX-670 program.

What Could Support a Move Toward the Target

The clearest bull case rests on ENTR-601-44, which has shown clinically meaningful functional gains, and on the higher-dose cohorts that could strengthen the efficacy and safety story. Analysts including TD Cowen and Evercore ISI have pointed to this program as a key catalyst. Entrada's cash, cash equivalents, and marketable securities have been guided to fund operations into 2027, reducing near-term dilution risk. The company also retains a clinical-stage partnership for VX-670 in myotonic dystrophy type 1, providing optionality beyond Duchenne. Institutional ownership remains high, and several large investors established positions during 2026.

What Could Prevent the Target From Being Reached

The principal obstacle is clinical. Roth MKM explicitly flagged that October ENTR-601-45 biomarker data disappointed, shifting attention to ENTR-601-44 — meaning a weak higher-dose readout could undermine the entire thesis. The shares already reflect skepticism: the price sits near the 52-week low, well below the 200-day moving average. With revenue falling sharply and EPS (earnings per share) deeply negative, valuation offers no floor. Insider selling, a downgrade from H.C. Wainwright, and the possibility of dilution or slower enrollment all represent additional headwinds. Any setback in the Duchenne program could compress the stock further rather than move it toward $19.

Technical Levels and Market Structure

Technically, TRDA is in a downtrend. It trades near its 52-week low of about $4.11 and below both its 50-day moving average (near $5.68) and its 200-day moving average (near $8.48). Those moving averages represent overhead resistance zones, while the $4.11 low is the key support level to monitor. The $10 level, corresponding to Roth MKM's target and a psychological round number, marks a notable intermediate milestone. A durable reclaim of the $8–$10 zone would be required before any move toward the higher analyst targets becomes structurally plausible.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though firms do not publish identical timelines, and for a clinical-stage company the effective horizon is often longer. Investors should watch the ENTR-601-44 longer-duration and higher-dose data (guided for the fourth quarter of 2026 and first quarter of 2027), any updates on ENTR-601-45, quarterly earnings and cash-burn figures, and further analyst target changes. Regulatory and enrollment milestones across the Duchenne franchise, along with any news on the partnered VX-670 program, will also shape the path toward the target. From what I see, tracking these catalysts closely is essential given the binary nature of the data.

Exploring AI Daily Buy/Sell Signals

In my research process, Tickeron's AI Daily Buy/Sell Signals have proven useful for monitoring volatile names like this one. The tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a clinical-stage biotech driven by news flow, these signals help identify momentum changes more efficiently than manual review alone, allowing traders to track opportunities and manage positions as data evolves.

Final Assessment

Can Entrada Therapeutics reach $19? The target — the average of four current analyst price targets spanning $10 to $25 — implies a roughly 270% gain from the stock's level near $5, a very large move that depends on clinical success rather than financial fundamentals. The bull case rests on ENTR-601-44's functional gains and upcoming higher-dose data, a cash runway into 2027, and the optionality of the VX-670 partnership. The bear case rests on disappointing ENTR-601-45 biomarkers, deep negative earnings, and a stock already near its lows. With such a wide analyst range and binary catalysts ahead, $19 is best understood as a multi-year upside scenario, not a forecast. Investors should monitor the ENTR-601-44 readouts, cash-burn trends, and analyst revisions before drawing conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TRDA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TRDA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for TRDA turned positive on October 28, 2026. Looking at past instances where TRDA's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TRDA's RSI Indicator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on TRDA as a result. In 74 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

Following a +15.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in 262 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 58 cases where TRDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

TRDA broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TRDA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.816) is normal, around the industry mean (3.592). P/E Ratio (-1.235) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. TRDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
One Design Center Place
Phone
+1 857 520-9158
Employees
152
Web
https://www.entradatx.com
Interact to see
Advertisement
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.